Circulating oxidized low-density lipoprotein: A biomarker of atherosclerosis and cardiovascular risk?

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 2, 2009, Pages 128-137

  Verhoye, Eline ^a   Langlois, Michel R ^a  

^a General Hospital St Jan   (Belgium)

Author keywords

Apolipoprotein B; Atherosclerosis; Cardiovascular disease; Oxidized low density lipoprotein (LDL); Small dense LDL

Indexed keywords

ALDEHYDE; ALKADIENE; APOLIPOPROTEIN; EPITOPE; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MATURATION; CONFERENCE PAPER; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FOAM CELL; HEART FUNCTION; HUMAN; IMMUNOASSAY; INFLAMMATION; ISCHEMIA; LIFESTYLE; LIPID OXIDATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SUBENDOTHELIUM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 59849121648     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.037     Document Type: Conference Paper

References (48)

1. Halevy D, Thiery J, Nagel D, Arnols S, Erdmann E, Höfling B, et al. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arteriosler Thromb Vasc Biol 1997;17:1432-7.
2. Chancharme L, Thérond P, Nigon F, Zarev S, Mallet A, Bruckert E, et al. LDL particle subclasses in hypercholesterolemia. Molecular determinants of reduced lipid hydroperoxide stability. J Lipid Res 2002;43:453-62.
3. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, et al. Increased circulating malondialdehydemodified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002;22:662-6.
4. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-80.
5. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
6. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
7. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low-density lipoprotein shows a positive relationship with the severity of acute coronary syndromes. Circulation 2001;103:1955-60.
8. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002;22:1162-7.
9. Ferretti G, Bachetti T, Nègre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7.
10. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1988;85:9748-52.
11. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2243-7.
12. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22:1649-54.
13. Sigurdadottir V, Fagerberg B, Wikstrand J, Schmidt C, Hulthe J. Circulating oxidized low-density lipoprotein is associated with echolucent plaques in the femoral artery independently of hsCRP in 61-year-old men. Atherosclerosis 2007;190:187-93.
14. Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation 2001;103:1930-2.
15. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
16. Ma FX, Zhou B, Chen Z, Ren Q, Lu SH, Sawamura T, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res 2006;47:1227-37.
17. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta J. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: a role of LOX-1. J Pharmacol Exp Ther 2002;302:601-5.
18. Mehta J. Oxidized or native low density lipoprotein cholesterol. J Am Coll Cardiol 2006;48:988-9.
19. Li D, Liu L, Chen H, Sawamura T, Mehta J. LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arteriosler Thromb Vasc Biol 2003;23:816-21.
20. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR; Multi-Ethnic Study of Atherosclerosis. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;194:245-52.
21. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-7.
22. Rietzschel ER, De Buyzere ML, Bekaert S, Segers P, De Bacquer D, Cooman L, et al. Rationale, design, methods and baseline characteristics of the Asklepios Study. Eur J Cardiovasc Prev Rehabil 2007;14:179-91.
23. Li D, Liu L, Chen H, Sawamura T, Mehta J. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003;107:612-7.
24. Bekaert S, De Meyer T, Rietzschel E, De Buyzere M, De Bacquer D, Langlois M, et al. The association between baseline telomere length and cardiovascular risk factors in a large, apparently healthy middle-aged population. Ageing Cell 2007;6:637-47.
25. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987;33:214-20.
26. Brouwers A, Langlois M, Delanghe J, Billiet J, De Buyzere M, Vercaemst R, et al. Oxidized low-density lipoprotein, iron stores, and haptoglobin polymorphism. Atherosclerosis 2004;176:189-95.
27. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J. Correlation between oxidized low density lipoproteins and coronary artery disease in heart transplant patients. Arteriosler Thromb Vasc Biol 1998;18:100-7.
28. Tsimakis S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003;41:360-70.
29. Van Hoydonck GA, Schouten E, Temme E. Reproducibility of blood markers of oxidative status and endothelial function in healthy individuals. Clin Chem 2003;49:963-4.
30. Langlois M, Rietzschel E, De Buyzere M, De Bacquer D, Bekaert S, Blaton V, et al. Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35-55 years (Asklepios Study). Arterioscler Thromb Vasc Biol 2008;28:1563-8.
31. Liu M-L, Ylitalo K, Salonen R, Salonen JT, Taskinen M-R. Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia families. Arterioscler Thromb Vasc Biol 2004;24:1492-7.
32. Cominacini L, Garbin U, Pastorino AM, Davoli A, Campagnola M, De Santis A, et al. Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 1993;99:63-70.
33. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-8.
34. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition Study. Arterioscler Thromb Vasc Biol 2003;23:1444-8.
35. Holvoet P, Kritchevsky S, Tracy R, Mertens A, Rubin S, Butler J, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, ageing, and body composition cohort. Diabetes 2004;53:1068-73.
36. Sjogren P, Basu S, Rosell M, Silveira A, de Faire U, Vessby B, et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:2580-6.
37. de Castro SH, Castro-Faria-Neto HC, Gomes MB. Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetes - a cross-sectional study. Rev Diabet Stud 2005;2:157-64.
38. Ikeda Y, Suehiro T, Yamanaka S, Kumon Y, Takata H, Inada S, et al. Association between serum ferritin and circulating oxidized low-density lipoprotein levels in patients with type 2 diabetes. Endocr J 2006;53:665-70.
39. Tsutsui T, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardiol 2002;39:957-62.
40. Rietzschel ER, Langlois M, De Buyzere ML, Segers P, De Bacquer D, Bekaert S, et al. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension 2008;52:535-41.
41. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
42. Ahmed E, Trifunovic J, Stegmayr B, Hallmans G, Lefvert AK. Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. Stroke 1999;30:2541-6.
43. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, et al. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008;59:224-9.
44. Vibo R, Kõrv J, Roose M, Kampus P, Muda P, Zilmer K, et al. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome. Free Radic Res 2007;41:282-7.
45. Uno M, Harada M, Takimoto O, Kitazato KT, Suzue A, Yoneda K, et al. Elevation of plasma oxidized LDL in acute stroke patients is associated with ischemic lesions depicted by DWI and predictive of infarct enlargement. Neurol Res 2005;27:94-102.
46. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005;112:812-8.
47. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 2006;48:973-9.
48. Wallenfeldt K, Fagerberg B, Wikstrand J, Hulthe J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 2004;256:413-20.